Caplin Point Laboratories's quarterly market cap
declined
from Sep. 2025 (₹149,447 Mil) to Dec. 2025 (₹139,718 Mil) and
declined
from Dec. 2025 (₹139,718 Mil) to Mar. 2026 (₹114,383 Mil).
Caplin Point Laboratories's annual market cap
increased
from Mar. 2024 (₹99,890 Mil) to Mar. 2025 (₹152,009 Mil) but then
declined
from Mar. 2025 (₹152,009 Mil) to Mar. 2026 (₹114,383 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Caplin Point Laboratories's Enterprise Value for Today is ₹184,149 Mil.
Caplin Point Laboratories (NSE:CAPLIPOINT) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Caplin Point Laboratories Market Cap Related Terms
Caplin Point Laboratories Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:CAPLIPOINT vs ZTS, UTHR: Market Cap Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Caplin Point Laboratories's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Caplin Point Laboratories Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Caplin Point Laboratories's Market Cap distribution charts can be found below:
* The bar in red indicates where Caplin Point Laboratories's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Caplin Point Laboratories (NSE:CAPLIPOINT) has a Market Cap of ₹194,468 Mil as of Jun. 30, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Caplin Point Laboratories and its competitors. According to the industry distribution chart, Caplin Point Laboratories ranks #153 out of 1020 companies in the Drug Manufacturers industry, placing it in the top 15%.
Is Caplin Point Laboratories' Market Cap too high?
Caplin Point Laboratories' current Market Cap is ₹194,468 Mil. Based on the distribution chart, Caplin Point Laboratories ranks #153 out of 1020 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Caplin Point Laboratories has a GF Score™ of 89/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Caplin Point Laboratories' Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Caplin Point Laboratories ranks #153 out of 1020 companies for Market Cap. This places Caplin Point Laboratories in the top 15% of its industry — outperforming the majority of peers. The industry median Market Cap is 213.67. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 213.67, based on 1,020 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Caplin Point Laboratories and its competitors. For the Drug Manufacturers industry, the median Market Cap is 213.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Caplin Point Laboratories's current Market Cap is ₹194,468 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caplin Point Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Caplin Point Laboratories (NSE:CAPLIPOINT) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,073.29, compared to a current price of ₹2,557.90 — trading 23.4% above its estimated fair value. The current Market Cap is ₹194,468 Mil. Caplin Point Laboratories' overall GF Score™ is 89/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Caplin Point Laboratories (NSE:CAPLIPOINT), the current Market Cap is ₹194,468 Mil as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Caplin Point Laboratories (NSE:CAPLIPOINT) Overvalued in 2026?
Based on GuruFocus' analysis, Caplin Point Laboratories stock appears to be overvalued.
The current stock price of ₹2,557.90 is trading 23.4% above its estimated GF Value™ of ₹2,073.29.
GuruFocus considers Caplin Point Laboratories to be Modestly Overvalued.
Key valuation signals for NSE:CAPLIPOINT:
Market Cap: ₹194,468 Mil
GF Value™: ₹2,073.29 vs. price of ₹2,557.90 (23.4% above fair value)
No single metric tells the full story. See the NSE:CAPLIPOINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Caplin Point Laboratories Ltd is an India-based pharmaceutical company. It is engaged in the manufacturing and marketing of pharmaceutical products. The company's key products include tablets, capsules, injections (liquid and lyophilized, prefilled syringes), ophthalmic solutions, liquid orals, soft gel capsules, ointments, creams, gels, powders for injections, suppositories, ovules, pre-mix bag formulations, inhalers, sprays, and IV infusions. It also provides pharmaceutical formulations in specialized injectable dosage forms and Ophthalmic drops.
89GF Score
Get the complete analysis for NSE:CAPLIPOINT
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CAPLIPOINT has been successfully added to your 
